ArticleBasic and clinical neuroscience2025
Clinical Efficacy and Safety of Dual Versus Single Antiplatelet Therapy in Lacunar Stroke.
Article in Basic and clinical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lacunar stroke, comprising 18% of ischemic stroke, is the second most common subtype of stroke in India. Available data on the effect of dual antiplatelet treatment with aspirin plus clopidogrel versus single antiplatelet therapy with aspirin alone, and their doses in lacunar stroke, are very limited. Our study aimed to investigate the efficacy, safety, and tolerability of dual versus single antiplatelet therapy in patients with a recent occurrence of lacunar stroke. Methods: This research was a prospective, single-center study conducted at the Department of Neurology. Patients with recent occurrence of lacunar stroke were randomly divided into 4 groups to receive aspirin 150 mg (group 1), aspirin 150 mg plus clopidogrel 75 mg (group 2), aspirin 75 mg plus clopidogrel 75 mg (group 3), and aspirin 75 mg (group 4) once daily. They were then closely monitored for 90 days. Results: A total of 360 patients were recruited and followed up for 90 days. The mean age of the patients was 57.8±14.1 years. Also, 188 patients (52.2%) were male. Recurrence of ischemic stroke occurred highest in group 4(22%), with no recurrence in group 2. Comparisons of recurrence of ischemic stroke between group 1 and group 4 (95% CI, 2.6829%, 31.73551%) and between group 3 and group 4 (95% CI, 3.9439%, 32.1542%) were significant (P<0.05). Haemorrhagic events occurred among recipients on dual antiplatelet therapy (DAPT). Conclusion: Efficacy-wise, group 2, which received 150 mg of aspirin plus 75 mg of clopidogrel, was found to be superior to the other groups in preventing lacunar stroke. Groups with DAPT manifested a worrisome trend of bleeding events.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.